Official websites use. Share sensitive information only on official, secure websites. You do not have permission under this licence to share adapted material derived from this article or parts of it. The SARS-CoV-2 vaccination campaign began in France in December targeting institutionalized older population before having been evaluated in this population. The objective of our study was to assess the tolerability of vaccination 21 days D21 and 90 days after the first vaccination D90 in institutionalized old people.
People living in nursing homes or in long-term hospitalization facilities in France were included Vaccine tolerability was prospectively assessed by the occurrence of health events at D21 and D90 local and systemic side effects, geriatric syndromes, cardiovascular events.
Vaccine efficacy was assessed by the occurrence of COVID and serious adverse events unscheduled hospitalization and all-cause mortality. There were no significant difference between the vaccinated and unvaccinated for systemic or local adverse events at D21 and D In this prospective cohort study, COVID vaccine in a very old institutionalized geriatric population had a reassuring safety profile and a protective effect on COVID, hospitalizations and deaths, cardiovascular events and pressure ulcers.
Since its transmission is mainly airborne, it has rapidly spread worldwide and was declared a global pandemic by the World Health Organization on March 11 th , [ 2 ]. Risk factors for death associated with COVID are older age median age 80 years , male gender, obesity and chronic heart, lung, kidney and liver diseases [ 6 ].
As the geriatric population is characterized by high age over 65 and multiple comorbidities, it has therefore been the most severely affected by this pathology. Although comorbid older individuals are the most affected by the pandemic, they have been largely underrepresented in randomized controlled trials and no institutionalized comorbid individuals over 80 have been included in those trials [ 7 β 11 ].
